← Back to Patent Explorer
US4228180A Expired / Lapsed US ⏱️ 0.0 years remaining

7-Oxabicycloheptane and 7-oxabicycloheptene prostaglandin analogs

Assignee: ER Squibb and Sons LLC
•
Filing: 1979-11-01
•
Granted: 1980-10-14
•
Expires: 1999-11-01
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract New 7-oxabicycloheptane and 7-oxabicycloheptene prostaglandin analogs which have the general formula ##STR1## wherein R 1 is hydrogen or lower alkyl; n is 0 to 4, m is 0 to 4 and x is 0 to 8, are useful as cardiovascular agents.

Inventors

  • 👤 Peter W. Sprague

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-31 14:29
CPC Classifications
C; C07; C07D; C07D493/00; C07D493/02; C07D493/08; A; A61; A61P; A61P11/00; A61P11/08; A61P7/00; A61P7/02; A61P9/00; A61P9/08; A61P9/10

Claims Analysis

Total Claims: 12
Claim 1
Independent Claim 30 words
A compound of the formula ##STR48## wherein R 1 is hydrogen or lower alkyl; n is 0 to 4, m is 0 to 4 and x is 0 to 8.
Claim 2
Dependent Claim 30 words
A compound of the formula ##STR48## wherein R 1 is hydrogen or lower alkyl; n is 0 to 4, m is 0 to 4 and x is 0 to 8.
Claim 3
Dependent Claim 13 words
The compound of claim 1 wherein n is 1 and m is 3.
Claim 4
Dependent Claim 24 words
The compound of claim 2 wherein x is 0 and the lower alkyl attached to the olefinic carbon atom contains 4 to 6 carbons.
Claim 5
Dependent Claim 10 words
The compound of claim 1 wherein R 1 is methyl.
Claim 6
Dependent Claim 10 words
The compound of claim 1 having the name [1R-(1α,2β(5Z),3β(1E),4α)]-7-[3-(1-octenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid.
Claim 7
Dependent Claim 10 words
The compound of claim 1 having the name [1R-(1α,2β(5Z),3β(1E),4α]-7-[3-(1-octenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid.
Claim 8
Dependent Claim 38 words
A method of inhibiting arachidonic acid-induced platelet aggregation and bronchoconstriction, which comprises administering to the circulatory system of a mammalian host an effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof.
Claim 9
Dependent Claim 26 words
The method as defined in claim 7 wherein said compound is administered in an amount within the range of from about 1 to about 100 mg/kg.
Claim 10
Dependent Claim 34 words
A composition for inhibiting arachidonic acid-induced platelet aggregation and bronchoconstriction, comprising an effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier therefor.
Claim 11
Dependent Claim 30 words
A method of inhibiting platelet aggregation which comprises administering to a mammalian host an effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof.
Claim 12
Dependent Claim 32 words
A method of inhibiting bronchoconstriction associated with asthma, which comprises administering to a mammalian host an effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof.

References Cited (Backward Citations)

US4112224A Cited
US4143054A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1983-10-14 1984-04-14 1984-10-14 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1987-10-14 1988-04-14 1988-10-14 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1991-10-14 1992-04-14 1992-10-14 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag